Assessing the Cost Utility of Response-Guided Therapy in Patients with Chronic Hepatitis C Genotype 1 in the UK Using the MONARCH Model
This analysis suggests that the treatment of HCV genotype 1 patients in fibrosis stage F2 has the greatest potential for maximizing health benefit and cost saving within an RGT protocol. Predicting those patients most likely to respond to treatments is important from both a clinical and cost perspective and the tailoring of treatment duration with the current standard of care is likely to remain a priority for payers with budgetary constraints. </AbstractSection> Copyright Springer International Publishing Switzerland 2013
Year of publication: |
2013
|
---|---|
Authors: | McEwan, Phil ; Kim, Ray ; Yuan, Yong |
Published in: |
Applied Health Economics and Health Policy. - Springer, ISSN 1175-5652. - Vol. 11.2013, 1, p. 53-63
|
Publisher: |
Springer |
Saved in:
Online Resource
Saved in favorites
Similar items by person
-
McEwan, Phil, (2010)
-
Bennett, Hayley, (2017)
-
McEwan, Phil, (2006)
- More ...